Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade Glioma: early-phase trial registry
32 of 43 indexed High Grade Glioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #339 of 28,707 conditions by registered trial count.
43 US clinical trials · 32 currently recruiting · #339 of 28,707 conditions by registered trial count
High Grade Glioma: 43 US clinical trials tracked, 32 recruiting.
High Grade Glioma is the subject of 43 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 8 of these trials.
Enrollment posture brief
Registry condition high-grade-glioma
OPEN 32 | RECR 74% | LATE 1 | EARLY 37 | RANK #339 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Burkitt Lymphoma (74% recruiting · 23 trials)
High Grade Glioma lists 32 open slots (74% of 43 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade Glioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade Glioma is recruiting above its size-band peers.
32 of 43 indexed trials (74.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates High Grade Glioma research.
Nationwide Children's Hospital accounts for 8 of 43 trials (18.6%). 30 distinct sponsors appear on at least one study for this condition label.
-
Most High Grade Glioma trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 43 trials that report a genuine target (sentinel values excluded). 38 of those (88.4%) plan for fewer than 100 participants.
-
High Grade Glioma research is mostly interventional.
41 interventional and 2 observational studies make up this index (95.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
43 total, page 1 of 1
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Jasper Gerritsen
NCT06118723
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Nationwide Children's Hospital
NCT05096481
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Dabrafenib and/or Trametinib Rollover Study
Novartis Pharmaceuticals
NCT03340506
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
St. Joseph's Hospital and Medical Center, Phoenix
NCT06072586
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
NCT06504381
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
NCT05278208
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
NCT06161974
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
NCT06528691
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Tcelltech
NCT06482905
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
NCT04485559
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05835687
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
NYU Langone Health
NCT06829173
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Baylor College of Medicine
NCT04099797
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Ashish Shah
NCT06264388
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Concurrent Azeliragon With Craniospinal Irradiation
NYU Langone Health
NCT06724926
Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma
Nader Sanai
NCT04559685
18F-Fluciclovine PET-MRI in High-grade Glioma
Children's Hospital of Philadelphia
NCT05553041
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Laminar Pharmaceuticals
NCT04299191
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
NCT06712875
STARLITE for Unresectable High-Grade Gliomas
University of Miami
NCT06428045
Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
University of Alabama at Birmingham
NCT05632562
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Nationwide Children's Hospital
NCT04254419
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Emory University
NCT06624371
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Wake Forest University Health Sciences
NCT05212272
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Nationwide Children's Hospital
NCT04655404
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Nader Sanai
NCT05773326
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Case Comprehensive Cancer Center
NCT05565118
A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Nationwide Children's Hospital
NCT03605550
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT03718767
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
Cellectar Biosciences
NCT05610891
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Sumitomo Pharma America
NCT05023551
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
University of Florida
NCT04573140
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)
University of Florida
NCT06946680
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato
NCT05561374
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
Memorial Sloan Kettering Cancer Center
NCT06209567
Low Dose Radiation Therapy for Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01466686
Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma
Alpheus Medical
NCT05362409
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT03355794
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 30 |
| Phase 2 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade Glioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade Glioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade Glioma page
43 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 32 High Grade Glioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nationwide Children's Hospital sponsors the most High Grade Glioma trials on record, review their full trial history before evaluating a specific study. See Nationwide Children's Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade Glioma condition card totals 43 registered trials; most-linked intervention Temozolomide; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.